- Home
- NXTC vs DFNS Comparison
NXTC vs DFNS Comparison
Compare NXTC & DFNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXTC | DFNS |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 49.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | NXTC | DFNS |
|---|---|---|
| Price | $12.83 | $2.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 24.5K | ★ 872.6K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,378,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $1.87 |
| 52 Week High | $15.74 | $2.44 |
Technical Indicators
Market Signals| Indicator | NXTC | DFNS |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | N/A |
| Support Level | $10.40 | N/A |
| Resistance Level | $13.47 | N/A |
| Average True Range (ATR) | 1.04 | 0.00 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 67.19 | 0.00 |
Price Performance
Historical ComparisonAbout NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.